Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TAK-935 Single Ascending Dose Study in Healthy Subjects
NCT02201056Phase 1Completed
- Sponsor
- Takeda
- Start
- Jul 2014
- Primary completion
- Jul 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of soticlestat in epilepsy (7 arms), sponsored by Takeda. Primary endpoints: Percentage of Participants Who Experience at Least One Treatment-emergent Adverse Event, Percentage of Participants Who Meet the Markedly Abnormal Criteria, for Safety Laboratory Tests at Least Once Post-dose and 2 more. Started Jul 2014; status: completed.
02
Drugs
soticlestat
03
Conditions
epilepsy
Beyond the preview
Go deeper on NCT02201056.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02201056.